These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34426482)

  • 1. Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals.
    Joosub I; Emara Z; Gray A
    Eur J Hosp Pharm; 2021 Sep; 28(5):280-283. PubMed ID: 34426482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the type and frequency of extemporaneous formulations dispensed in hospital and community pharmacies.
    Ramtoola Z; Catibusic A; Ameen H; Cullen S; Barlow JW
    Explor Res Clin Soc Pharm; 2023 Dec; 12():100380. PubMed ID: 38146320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extemporaneous compounding activities and the associated informational needs of pharmacists.
    Crawford SY; Dombrowski SR
    Am J Hosp Pharm; 1991 Jun; 48(6):1205-10. PubMed ID: 1858798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical appraisal of commercially available suspending vehicles for extemporaneous compounding of cardiovascular medicines: physical and chemical stability mini review.
    Thrimawithana TR; D'Amore S; Dib Y; Fadavi Firooz N; Fakhouri W; Saeed A; Allahham A
    Pharm Dev Technol; 2019 Jun; 24(5):529-538. PubMed ID: 30238838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extemporaneous compounding in veterinary practice: a New Zealand perspective.
    Gargiulo DA; Chemal C; Joda L; Lee YJ; Pilkington M; Haywood A; Garg S
    N Z Vet J; 2013 Nov; 61(6):311-5. PubMed ID: 23544952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extemporaneous Compounding: Selective Pharmacists with Separate Skill.
    Mohiuddin AK
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, Scope and Quality of Extemporaneous Medications in Selected Healthcare Facilities and Implications for Pharmacy Practice.
    Allotey-Babington GL; Akwo Kretchy I; Atiapa Asiedu E; Kelly Amuakwa M; Akwele Seaneke O; Ankrah D; Kwadwo Somuah A; Dei Owusu-Nyamekye A; Owusu-Ansah S; Kwame Effah P; Debrah J; Acheampomaa Nai E; Owusu E; Lamptey W; Gyekye IJA; Nettey H
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779112
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Devices for securing and administering pediatric compounded oral liquids: survey results from French university hospitals.
    Cavelier M; Hervouët C; Varin R; Gondé H
    Eur J Pediatr; 2024 Jun; 183(6):2805-2810. PubMed ID: 38573361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extemporaneous compounding in a sample of New Zealand hospitals: a retrospective survey.
    Kairuz T; Chhim S; Hasan F; Kumar K; Lal A; Patel R; Singh R; Dogra M; Garg S
    N Z Med J; 2007 Mar; 120(1251):U2466. PubMed ID: 17384694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formulations.
    Belayneh A; Tessema Z
    ScientificWorldJournal; 2021; 2021():8523091. PubMed ID: 34955693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practices of pharmacies that compound extemporaneous formulations.
    Treadway AK; Craddock D; Leff R
    Am J Health Syst Pharm; 2007 Jul; 64(13):1403-9. PubMed ID: 17592006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in compounding of oral liquids for pediatric patients: a patient safety concern.
    Rood JM; Engels MJ; Ciarkowski SL; Wagenknecht LD; Dickinson CJ; Stevenson JG
    J Am Pharm Assoc (2003); 2014; 54(4):383-9. PubMed ID: 25063260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.